Ken Watanabe

Title: Ken Watanabe: Innovator in Therapeutic Agent Screening

Introduction

Ken Watanabe is a notable inventor based in Obu, Japan. He has made significant contributions to the field of therapeutic agent screening, particularly in relation to disuse muscular atrophy. His innovative approach has garnered attention in the scientific community.

Latest Patents

Watanabe holds a patent for a method that screens therapeutic agents for disuse muscular atrophy. This method involves the interaction between a selected protein and a polyubiquitin chain in the presence of a candidate therapeutic agent. The effectiveness of the candidate is determined by observing the binding strength between the protein and the polyubiquitin chain. This can be assessed through various techniques, including enzyme-linked immunosorbent assay, NMR spectroscopy, X-ray crystal analysis, electron microscopy, or surface plasmon resonance.

Career Highlights

Throughout his career, Watanabe has worked with esteemed institutions such as the National Institute of Advanced Industrial Science and Technology and the National Center for Geriatrics and Gerontology. His work has focused on advancing the understanding of muscular atrophy and developing potential therapeutic solutions.

Collaborations

Watanabe has collaborated with Tohru Natsume, contributing to the advancement of research in his field.

Conclusion

Ken Watanabe's innovative methods in screening therapeutic agents represent a significant advancement in the fight against disuse muscular atrophy. His contributions continue to influence research and development in this important area of health.